Cetuximab (Erbitux®) (mAb Based) ELISA Assay Kit

$1,190.00

The Eagle Biosicences Cetuximab mAb-based ELISA Assay Kit is an enzyme immunoassay for the specific and precise determination of free Cetuximab in serum and plasma. The Eagle Biosciences Cetuximab mAb-based ELISA Assay Kit is for research use only and not to be used in diagnostic procedures.

Cetuximab (Erbitux®) (mAb Based) ELISA Assay Kit

For Research Use Only

Size: 1 x 96 wells
Sensitivity: 2 ng/mL
Dynamic Range: 6 -200 ng/mL
Incubation Time: < 2 hours
Sample Type:  Serum, Plasma
Sample Size: 10 µL

Additional Information

Assay Background

The drug Cetuximab (trade name Erbitux®) is a human-mouse chimeric immunoglobulin (Ig) G1k monoclonal antibody (mAb), selectively directed against the epidermal growth factor receptor (EGFR), also known as HER1 or ErbB1. Since its approval by Food and Drug Administration for cancer treatment in 2004, Cetuximab became widely used in the treatment of colorectal and head and neck cancers. The ImmunoGuide Cetuximab ELISA  (mAb-based) kit can be efficiently used for measuring free Cetuximab levels in serum and plasma.

Assay Principle

The Eagle Biosciences Cetuximab ELISA is based on Cetuximab-specific mouse monoclonal antibody (catcher Ab, ImmunoGuide clone IG-FB7D9). Diluted standards and diluted samples are incubated in the microtiter plate coated with IG-FB7D9 mAb. After incubation, the wells are washed. A horseradish peroxidase (HRP)-conjugated anti-human IgG monoclonal antibody is added and binds to the Fc part of Cetuximab. Following incubation, wells are washed and the bound enzymatic activity is detected by addition of chromogen-substrate. The colour developed is proportional to the amount of Cetuximab in the sample or standard. Results of samples can be determined by using the standard curve. Binding of Cetuximab to the solid phase, pre-coated with IG-FB7D9, is inhibited by recombinant human epidermal growth factor receptor (rh-EGFR) protein in a concentration dependent manner. Therefore, the ImmunoGuide Cetuximab ELISA (mAb-Based) measures the free form of Cetuximab.


Typical Standard Curve

Manual

Product Manual


Publications

Citations

  • Tabernero J, Ciardiello F, Rivera F, Rodriguez-Braun E, Ramos FJ, Martinelli E, Vega-Villegas ME, Roselló S, Liebscher S, Kisker O, Macarulla T, Baselga J, Cervantes A. Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. Ann Oncol. 2010;21(7):1537-45.
  • Zhu AX, Stuart K, Blaszkowsky LS, Muzikansky A, Reitberg DP, Clark JW, Enzinger PC, Bhargava P, Meyerhardt JA, Horgan K, Fuchs CS, Ryan DP. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer. 2007;110(3):581-9.
  • Tan AR, Moore DF, Hidalgo M, Doroshow JH, Poplin EA, Goodin S, Mauro D, Rubin EH. Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors. Clin Cancer Res. 2006;12(21):6517-22.
  • Lu X, Chen X, Sun J, Gao P, Song Y, Huang X, Luo Y, Chen P, Wang Z. Polymorphism in epidermal growth factor is related to clinical outcomes of metastatic colorectal cancer patients treated with cetuximab: a systematic review and meta-analysis. Int J Clin Exp Med. 2015;8(7):10929-37.
  • Boeckx C, Blockx L, de Beeck KO, Limame R, Camp GV, Peeters M, Vermorken JB, Specenier P, Wouters A, Baay M, Lardon F. Establishment and characterization of cetuximab resistant head and neck squamous cell carcinoma cell lines: focus on the contribution of the AP-1 transcription factor. Am J Cancer Res. 2015;5(6):1921-38.
  • Kurokawa M, Watanabe Nemoto M, Harada R, Kobayashi H, Horikoshi T, Kanazawa A, Togasaki G, Abe Y, Chazono H, Hanazawa T, Okamoto Y, Uno T. Initial experience of radiotherapy plus cetuximab for Japanese head and neck cancer patients. J Radiat Res. 2015;56(5):849-55.
    de Boer E, Warram JM, Tucker MD, Hartman YE, Moore LS, de Jong JS, Chung TK, Korb ML, Zinn KR, van Dam GM, Rosenthal EL, Brandwein-Gensler MS. In Vivo Fluorescence Immunohistochemistry: Localization of Fluorescently Labeled Cetuximab in Squamous Cell Carcinomas. Sci Rep. 2015 Jun 29;5:10169. doi: 10.1038/srep10169
  • Fiorentini G, Aliberti C, Sarti D, Coschiera P, Tilli M, Mulazzani L, Giordani P, Graziano F, Gonzalez AM, Marcos RG, Mugnoz FG, Cantore M, Ricci S, Catalano V, Mambrini A. Locoregional therapy and systemic cetuximab to treat colorectal liver metastases. World J Gastrointest Oncol. 2015;7(6):47-54.
    Hecht JR, Douillard JY, Schwartzberg L, Grothey A, Kopetz S, Rong A, Oliner KS, Sidhu R. Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer. Cancer Treat Rev. 2015;41(8):653-9.
  • Li XX, Liang L, Huang LY, Cai SJ. Standard chemotherapy with cetuximab for treatment of colorectal cancer. World J Gastroenterol. 2015;21(22):7022-35.
    Shih YH, Peng CL, Lee SY, Chiang PF, Yao CJ, Lin WJ, Luo TY, Shieh MJ. 111In-cetuximab as a diagnostic agent by accessible epidermal growth factor (EGF) receptor targeting in human metastatic colorectal carcinoma. Oncotarget. 2015;6(18):16601-10.
  • Song QB, Wang Q, Hu WG. Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: a meta-analysis. World J Gastroenterol. 2015;21(14):4365-72.
  • Tsukihara H, Nakagawa F, Sakamoto K, Ishida K, Tanaka N, Okabe H, Uchida J, Matsuo K, Takechi T. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts. Oncol Rep. 2015;33(5):2135-42.
  • Takahashi N, Yamada Y, Furuta K, Nagashima K, Kubo A, Sasaki Y, Shoji H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Hamaguchi T, Shimada Y. Association between serum ligands and the skin toxicity of anti-epidermal growth factor receptor antibody in metastatic colorectal cancer. Cancer Sci. 2015;106(5):604-10.
  • Stintzing S. Management of colorectal cancer. F1000Prime Rep. 2014 Nov 4;6:108. doi: 10.12703/P6-108. eCollection 2014. Review.
    Shirao K, Yoshino T, Boku N, Kato K, Hamaguchi T, Yasui H, Yamamoto N, Tanigawara Y, Nolting A, Yoshino S. A phase I escalating single-dose and weekly fixed-dose study of cetuximab pharmacokinetics in Japanese patients with solid tumors. Cancer Chemother Pharmacol. 2009;64(3):557-64.
  • Gao B, Yeap S, Clements A, Balakrishnar B, Wong M, Gurney H. Evidence for therapeutic drug monitoring of targeted anticancer therapies. J Clin Oncol. 2012;30(32):4017-25.
  • Cézé N, Ternant D, Piller F, Degenne D, Azzopardi N, Dorval E, Watier H, Lecomte T, Paintaud G. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of cetuximab. Ther Drug Monit. 2009;31(5):597-601.